Multicenter, Open-label, Single Arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan’s Tolerance in Patients With Metastatic Triple-Negative Breast Cancer.

ENSAYO CLÍNICO CON MEDICAMENTOS